

Supplementary Table 2. Comparison of clinical characteristics and baseline histological parameters between *HSD17B13* rs72613567 genotypes among 223 biopsy-proven NAFLD patients

Characteristic	NAFLD (n=223)			P-value
	T/T (n=133)	T/TA (n=72)	TA/TA (n=18)	
Age (years)	55.2±12.1	56.2±12.2	56.1±16.3	0.644
Gender				0.151
Male	76 (57.1)	31 (43.1)	10 (55.6)	
Female	57 (42.9)	41 (56.9)	8 (44.4)	
Ethnicity				0.016
Malay	59 (44.4)	43 (59.7)	11 (61.1)	
Chinese	36 (27.1)	18 (25.0)	7 (38.9)	
Indian	38 (28.6)	11 (15.3)	0 (0.0)	
BMI (kg/m ²)	29.2±4.7	28.7±4.6	29.2±4.8	0.854
HbA1c (%)	6.5±1.5	6.5±1.3	6.7±2.2	0.958
Total cholesterol (mmol/L)	5.1±1.2	5.2±1.0	4.8±1.1	0.211
Triglyceride (mmol/L)	1.7±0.6	1.8±0.8	1.6±0.6	0.929
HDL (mmol/L)	1.2±0.3	1.3±0.3	1.2±0.4	0.047
LDL (mmol/L)	3.2±1.1	3.2±0.9	2.8±1.0	0.264
ALT (U/L)	85.4±50.7	73.2±34.7	85.2±56.9	0.547
AST (U/L)	46.8±27.4	42.8±19.8	47.4±35.2	0.894
GGT (U/L)	102.4±102.0	117.9±121.8	95.3±64.0	0.817
Steatosis grade	1.8±0.7	2.2±0.8	2.1±0.8	0.057
Lobular inflammation	1.4±0.6	1.4±0.6	1.4±0.5	0.854
Hepatocyte ballooning	1.1±0.6	1.0±0.7	1.2±0.7	0.464
Fibrosis	1.4±1.0	1.4±1.1	1.7±1.2	0.759

Values are presented as mean±standard deviation or number (%).

All *P*-values were obtained using Kruskal-Wallis test. Significance was assumed when *P*<0.05.

HSD17B13, 17β-hydroxysteroid dehydrogenase 13; NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; HbA1c, haemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase.